Jeff is the CEO of Vividion Therapeutics. Jeff joined Vividion as Chief Executive Officer in November 2020, bringing more than 35 years of successful industry leadership, having held multiple senior executive, CEO, and board director roles during his career at both Fortune 500 pharmaceutical and emerging biotechnology companies.

Among Mr. Hatfield’s many career leadership roles, he previously served as the CEO of Vitae Pharmaceuticals, Inc., a pioneer in computational structure-based drug discovery, where he led the company from start-up to clinical-stage advancement of multiple first-in-class programs, and ultimately to its $640 million acquisition by Allergan Plc. Earlier, he served as a senior executive at Bristol-Myers Squibb (BMS), where he held roles including senior vice president, Immunology and Virology Divisions; president, BMS-Canada; and head of U.S. market access. Mr. Hatfield currently serves on the board of directors of Vir Biotechnology, Inc., aTyr Pharma and miRagen Therapeutics. He also serves as a Key Advisory Board member for the Harvard Business School’s Blavatnik Fellowship in Life Science Entrepreneurship, and is a faculty member at Purdue University, where he teaches entrepreneurship to doctoral students. Mr. Hatfield holds an MBA from The Wharton School of the University of Pennsylvania and a B.S. in pharmacy from Purdue University.